Andere Sprachen Zomedica Corp.

Aktien

A2QEF3

CA98980M1095

ZOM

Markt geschlossen - Nyse Andere Börsenplätze 22:00:00 02.05.2024			% 5 Tage	% 1. Jan.
0,142 ^USD	+0,28 %		+9,15 %	-29,07 %

01.04.	Zomedica Corp. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
01.04.	Zomedica sucht Akquisitionen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Zomedica to Report First Quarter 2024 Financial Results and Provide Business Update on May 9th at 4:30 p.m. ET	01.05.
Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024	10.04.
Zomedica Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
Zomedica Seeks Acquisitions	01.04.
Earnings Flash (ZOM) ZOMEDICA Posts Q4 Revenue $7.3M	01.04.
Zomedica Corp. Reiterates Revenue Guidance for Full Year 2024	01.04.
Zomedica Announces Publication of Research Concluding TRUFORMA Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay Platform	15.03.
Zomedica Corp. Announces Publication of Research Con Including TRUFORMA(R) Platform Is More Accurate Diagnostic Test for Feline Hyperthyroidism Than Chemiluminescent Immunoassay Platform	14.03.
Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences	13.03.
Zomedica Announces Publication of Case Series Highlighting Success with PulseVet Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogs	08.03.
Zomedica to Present at the Sidoti Small Cap Conference March 14, 2024	06.03.
Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences	09.02.
Zomedica to Host Virtual Investor Day February 13 at 3:00 p.m. ET	07.02.
Open Letter to Zomedica Shareholders from your Chief Executive Officer	01.02.
Zomedica to Participate in the Lytham Partners 2024 Investor Select Conference	31.01.
Zomedica Pharmaceuticals Reports Preliminary Q4 Revenue	17.01.
Zomedica Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Full Year 2024	17.01.
Zomedica Corp. to Host Conference Call on January 17, 2024, at 4:30 p.m. ET to Provide a Business Update, Preliminary 2023 Revenue and Cash Position	11.01.
Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel 'X-Trode' Handpiece	05.01.
Zomedica Corp. Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease	18.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Zomedica Corp.

Aktien

A2QEF3

CA98980M1095

ZOM

Andere Sprachen

Filter